Press Releases
Samsung Biologics receives ‘Grade A’ rating on ESG evaluation from the Korea Institute of Corporate Governance & Sustainability
Samsung Biologics announced today that the company received a “Grade A” from the Korea Institute of Corporate Governance and Sustainability (KCGS), a non-profit corporate governance service provider and global think tank focused on enhancing ESG policies across organizations. Modeled off international standards, KCGS’s comprehensive ESG evaluation reviews the environmental management, social responsibility, and governance structure for all companies listed on the Korea Stock Exchange.
“Samsung Biologics is honored to be recognized by the KCGS for our ESG efforts,” said John Rim, CEO and President of Samsung Biologics. “As part of our vision to build a healthier future for all while creating sustainable value, we will continue to invest in environment-conscious practices to mitigate the risks of climate change, social contribution activities that give back to our communities, and transparent practices in our board and governance structure.”
Operating under ISO 50001 Energy Management and ISO 45001 Occupational Health & Safety Management, the company’s environmental strategy outlines a number of core activities to reduce emissions, including process energy optimization and minimizing the use of disposables in the manufacturing process through waste management, while disclosing risks and opportunities through the Carbon Disclosure Project (CDP). Samsung Biologics is also engaging its suppliers and partners to drive successful decarbonization throughout the supply chains in a number of global initiatives such as Frontier 1.5D and the Sustainable Markets Initiative.
The company has also conducted various social contribution activities to develop the local community. In partnership with the Incheon Human Resources Development Foundation, Samsung Biologics created a youth scholarship and mentoring program to provide financial support and career counseling to underprivileged students. It also started a medical expense aid in 2013 to support medical expenses for disadvantaged patients at local Incheon hospitals.
Samsung Biologics also strengthened its corporate transparency by ensuring compliance with laws and ethics is a top management principle. Last year, it established an ESG committee under its Board of Directors as well as an internal accounting evaluation group under its Audit committee. Its robust Business Continuity Management System (BCMS) helps increase organizational resilience and assimilates business continuity awareness and activities into its general operations. The company also minimizes potential risks and strengthens responsibility towards human rights, health and the environment through prevention training, rigorous reporting and monitoring, and follow-up management.
For more details and continuous updates on sustainability activities, please visit the Sustainability page.
Samsung Biologics announced today that the company received a “Grade A” from the Korea Institute of Corporate Governance and Sustainability (KCGS), a non-profit corporate governance service provider and global think tank focused on enhancing ESG policies across organizations. Modeled off international standards, KCGS’s comprehensive ESG evaluation reviews the environmental management, social responsibility, and governance structure for all companies listed on the Korea Stock Exchange.
“Samsung Biologics is honored to be recognized by the KCGS for our ESG efforts,” said John Rim, CEO and President of Samsung Biologics. “As part of our vision to build a healthier future for all while creating sustainable value, we will continue to invest in environment-conscious practices to mitigate the risks of climate change, social contribution activities that give back to our communities, and transparent practices in our board and governance structure.”
Operating under ISO 50001 Energy Management and ISO 45001 Occupational Health & Safety Management, the company’s environmental strategy outlines a number of core activities to reduce emissions, including process energy optimization and minimizing the use of disposables in the manufacturing process through waste management, while disclosing risks and opportunities through the Carbon Disclosure Project (CDP). Samsung Biologics is also engaging its suppliers and partners to drive successful decarbonization throughout the supply chains in a number of global initiatives such as Frontier 1.5D and the Sustainable Markets Initiative.
The company has also conducted various social contribution activities to develop the local community. In partnership with the Incheon Human Resources Development Foundation, Samsung Biologics created a youth scholarship and mentoring program to provide financial support and career counseling to underprivileged students. It also started a medical expense aid in 2013 to support medical expenses for disadvantaged patients at local Incheon hospitals.
Samsung Biologics also strengthened its corporate transparency by ensuring compliance with laws and ethics is a top management principle. Last year, it established an ESG committee under its Board of Directors as well as an internal accounting evaluation group under its Audit committee. Its robust Business Continuity Management System (BCMS) helps increase organizational resilience and assimilates business continuity awareness and activities into its general operations. The company also minimizes potential risks and strengthens responsibility towards human rights, health and the environment through prevention training, rigorous reporting and monitoring, and follow-up management.
For more details and continuous updates on sustainability activities, please visit the Sustainability page.